Recombinant Zika vaccines
US11110162B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 23, 2016 |
| Grant date | Sep 7, 2021 |
| Priority date | — |
| Expiry date | Dec 23, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldChemical engineering
- WIPO sectorChemistry
Abstract
The present invention relates to the provision of immunogenic or vaccine compositions comprising at least one recombinant Zika virus antigen, wherein the at least one recombinant Zika virus antigen is encoded by at least one nucleic acid sequence encoding at least one E-protein of a Zika virus or a functional fragment thereof. Further provided are nucleic acid molecules and a recombinant chimeric virus encoding and/or comprising selected antigens from a Zika virus, which are suitable as vaccine compositions. Preferably, the sequences encoding at least one Zika virus antigens suitable for eliciting an immune response are operably linked to a non-flavivirus derived vector backbone. Further provided are methods for purifying the recombinant chimeric virus particles or the immunogenic composition. Finally, there is provided an immunogenic/vaccine composition for use in a method of preventing or treating a Zika virus disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.